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Methods & Materials: Soldiers in the Belgian Defence are intra-
dermally vaccinated for rabies pre-deployment since 2008by a four
injection schedule (day 0,7, 28, 365). Neutralizing antibody titers
against rabies were tested 7 days after booster vaccination. Sero-
logy results of subjects, vaccinated between the 1st of april 2008
and the 31st of june 2013, were evaluated. A titer of the Rapid Flu-
orescent Focus Inhibition Test (RFFIT) ≥ 0,5 IU/ml is considered
to be boostable. A titer > 3,0 IU/ml is considered to give sufﬁcient
protection and>10 IU/ml a long-lasting immunity.
Results: 6598 subjects started pre-exposure rabies vaccination
in the Belgian Army in these period. 1658 subjects were excluded
due to lack of certainty of intradermal injection method 4940 sub-
jects started intradermal rabies vaccination 4285 ﬁnished initial
vaccination (d0, 7, 28) 1363 had a fourth vaccination (booster) 881
had a serology test (RFFIT) done after booster vaccination Median
age was 36.4 year (with a standard deviation of 9,2), Gender was in
96.1% male. Neutralizing Antibodies were as follows: - 100% (881)
of subjects had RFFIT above 0,5 IU/ml; - 83,3% (734) of subjects had
a long-lasting immunity whit RFFIT above 10 IU/ml; - 96.6% (851)
of subjects had a RFFIT above 3.0 IU/ml. We observed a delay in
days of serology testing (mean=145 (SD 6,3/range 7–1603).
Conclusion: The Classical (day 0, 7, 28, 365) Intradermal Pre-
exposureVaccination is Immunogenic andVery Promising to tackle
the problem of Volume Shortage in Biologicals worldwide. Neu-
tralizing Antibodies after four intradermal rabies injections are
considered to be boostable in 100% of cases and protective in 96,6%
of subjects in this largest cohort of intradermal vaccination world-
wide.
http://dx.doi.org/10.1016/j.ijid.2014.03.1325
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Progress towards elimination of rubella and
congenital rubella syndrome in Singapore: Are
we there yet?
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Background: Singapore has a comprehensive national child-
hood immunization programme which includes rubella. The
objectives of this study were to describe the epidemiology of
rubella in Singapore from 2003 to 2012, and assess its progress
in implementing key control strategies against the disease, mea-
sured against the targets set by the World Health Organization
(WHO) Western Paciﬁc Regional Ofﬁce (WPRO) of reducing rubella
and congenital rubella syndrome (CRS) incidence to below 10
indigenous cases per million population and 10 cases per million
live-births, respectively, by 2015.
Methods & Materials: Epidemiological data on all suspected
and laboratory-conﬁrmed rubella cases notiﬁed to the Ministry of
Health for the period 2003-2012 were used. Data on vaccination
coverage was obtained from the National Immunization Registry.
To assess population immunity against rubella, two National Sero-
prevalence Surveys (NSS) were conducted based on residual blood
samplesof adult residents fromtheNationalHealthSurveys in2004
and 2010.
Results: The incidence of rubella ranged from12–37 permillion
population during the 10-year period. The age-speciﬁc incidence
rate of rubella was the highest in children below 5 years of age.
The incidence of indigenous cases decreased from 36.2 in 2008 to
10.7 per million population in 2012. The susceptibility to rubella
in women aged18-44 years decreased signiﬁcantly from 15.8% in
2004 to 11.0% in 2010 (p=0.001). Non-residents constituted 51%
of the cases notiﬁed among women in this reproductive age group.
There were nine cases of CRS reported during this period, and over
66% were imported cases. In the past decade, the annual vaccina-
tion coverage against measles, mumps and rubella (MMR) among
Singapore residents at 2 years of age and students aged 11-12 years
had been maintained between 93% and 96%. For school entrants
aged 6-7 years and those aged 11 years, the annual coverage rate
was between 92% and 95% from 2008 to 2012.
Conclusion: Singapore has made progress and is on track
towards elimination of rubella and CRS. The NCIP has been suc-
cessful in increasing the population immunity against rubella and
preventing CRS through concerted efforts. The current high vacci-
nation coverage and vigilant case surveillance should be sustained.
http://dx.doi.org/10.1016/j.ijid.2014.03.1326
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Background: Cytokines play a crucial role in immune response.
The inﬂuence of synthetic oligosaccharides on the cytokine produc-
tion is not completely investigated. Aim. The study of the cytokine
production in mice in response to a conjugate of a synthetic hexas-
accharide fragment of the capsular polysaccharide of S.pneumoniae
type 14 and BSA as a model protein carrier.
Methods & Materials: The hexasaccharide-BSA conjugate (HC)
was prepared by the squarate method and contained, according
to the MALDI-TOF data, 18 hexasaccharide residues on average.
Sera from mice after immunization with HC were tested in ﬂow
cytometry using test system FlowCytomixMouse Thl/Th2 10plex
(BenderMedSystems). The subisotypes of IgG were determined in
ELISA using HC as a well-coating antigen. The protective activity
of HC was evaluated by challenge of the immunized mice with S.
pneumoniae type 14.
Results: Intraperitoneal injection of HC adsorbed on alum
hydroxide in CBA mice led to appearance of IL-1, IL-5, IL-6, IL-10,
IL-17, TNF, GM-CSF that increased in 2hours and remained at the
same level within 24hours as compared with control mice. Bichro-
matic increase in concentration of IFN began to rise later - 4h after
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HC administration, and reached the maximal value (19.2pg/ml)
at the end of 24hours considerably exceeding that in the control
group (3pg/ml). Therefore, after immunizationwithHC, leukocytes
producedTh1, Th2andTh17cytokines,whichplay thedifferent role
in the immune response regulation. The obtained data explain the
predominant production, in mice immunized with HC, of IgG1 and
IgG2a subisotypes to the capsular polysaccharide of S. pneumoniae
14, which are connected with IL-5 and IFN production respec-
tively. IL-17 produced by CD4+IL17+ stimulates the protection from
extracellular bacteria including S. pneumoniae that was proved by
challenging immunized mice with a lethal dose of S. pneumoniae
type 14. As a result, all immunizedmice survived as comparedwith
10% survival in the control group.
Conclusion: The ability of the hexasaccharide conjugate to
stimulate production of Th1, Th2 and Th17 cytokines with the
following production of IgG antibodies to the capsular polysaccha-
ride explains its protective activity in mice after challenge with
S.pneumoniae type 14.
http://dx.doi.org/10.1016/j.ijid.2014.03.1327
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Comparison of immunogenicity elicited by two
prime-boost strategies against tuberculosis
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Background: Tuberculosis remains a major health problem
worldwide, and the efﬁcacy of the only available vaccine Bacille
Calmette-Guérin (BCG) varies from 0% to 80%. It is extremelyur-
gentto ﬁnd new vaccine candidates and develop novel vaccine
approaches. The disease is caused by Mycobacterium tuberculo-
sis whose preferred habitat is the host macrophage, and cellular
immune responses are important in against intracellular bacte-
rial infection. An efﬁcacious tuberculosis (TB) vaccinewill probably
need to induce both CD4+and CD8+T-cell responses speciﬁc to a
protective Mycobacterium tuberculosis antigen(s). The gene Rv1769
has been lost from BCG-Pasteur1173 in vitro subculture, and some
studies have demonstrated that it is excellent T cell antigen. To
evaluate its immunogenicity, we used the prime-boost strategy to
immunize BALB/c mice and detected its cellular immune response.
Methods&Materials: In our research, we immunized 4-5week
old pathogen-free BALB/cmalemice byDNA/DNAandDNA/protein
prime-boost vaccination strategies. Mice were killed 4, 8, 12, 16
weeks after the last boost, and we detected antibody titers in the
serum, the proliferation rate of splenocytes, percentage of CD4+
and CD8+ T cells in the splenocytes and the IFN- and IL-4 levels
in special antigen-stimulated splenocyte cultures to measure its
immunogenicity. Measurement of these data are expressed as the
mean± standard errors(S.E.). Differences among the groups were
analyzed by one-way ANOVA and differences between two groups
wereanalyzedbyPostHocTest and thedifferenceswereconsidered
statistically signiﬁcant for P <0.05.
Results: Our data suggests that our novel DNA/DNA using
Rv1769 vaccine could elicit the most long-lasting and strongest
Th1 type cellular immune responses involving CD4+ and CD8+ T
cells. This response is characterized by a strong antibody response,
the proliferation rate of splenocytes, a high percentage of CD4+
and CD8+ T cells and high levels of IFN- in antigen-stimulated
splenocyte cultures.
Conclusion: Our results provide evidence that the gene Rv1769
is a potential antigen or subunit vaccine to TB for further study, and
in the future, we would consider build an in vivo challenge model
to extend our ﬁndings to an infection/disease protection system.
http://dx.doi.org/10.1016/j.ijid.2014.03.1328
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Background: We evaluated the feasibility and acceptability of
a new presentation of liquid DTP-HepB-Hib vaccine in a UnijectTM
device in Senegal and Vietnam.
Methods&Materials:We conducted306 interviews, nine focus
groupsessions, observationsof immunizationsessions (using injec-
tion into an orange), and a desk review of national programmatic
documents. Interviews were conducted with health workers, pro-
fessional representatives, andcaretakers.Weassessed the logistical
impact of UnijectTM with theWHO-developed immunization logis-
tics planning tool.
Results: Interviewees emphasizedefﬁcacy and safety as key fac-
tors for acceptability of a new device and most perceived that the
UnijectTM device represented an improvement over existing vac-
cine presentations. Compared to current presentations, UnijectTM
reducedvaccinewasteweight andvolume, including thenumberof
empty vials (from 51% in Vietnam to 68% in Senegal). By bundling
needles and syringes, UnijectTM reduced the potential for stock-
outs of one or the other. Time per vaccinated child decreased by
27%-61% depending on the setting.Each country used more than
one DTP-HepB-Hib vaccine presentation, and UnijectTM decreased
overall cold chain requirements formost butnot all of thesepresen-
tations. Informants reported thatUniject’sTM relatively lightweight
compared to traditional auto-disabled syringes should facilitate
both outreach and mobile strategies. Challenges also were identi-
ﬁed. As a novel injection device, some stakeholders may require
reassurance that UnijectTM represents contextually appropriate
technology. Vaccinator training will be required to address several
technical issues (e.g., activating the device and themotion required
for vaccine delivery) and perceptions (e.g., that the plastic reservoir
might freeze more easily and be difﬁcult to handle). A key concern
was that the UnijectTM device was used already in Senegal for con-
